Dee Rapposelli

In patients with knee OA, intra-articular ozone may provide pain relief, functional improvement, and gains of QoL.

Individuals with new-onset rheumatoid arthritis are at increased risk of acute coronary syndrome.

Radiofrequency denervation of thoracic facet joints may provide pain relief comparable to pain relief achieved for cervical and lumbar facet joints.

The domains for outcome measurement in clinical trials of psoriatic arthritis were updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and endorsed by Outcome Measures in Rheumatology.

The domains for outcome measurement in clinical trials of psoriatic arthritis were updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and endorsed by Outcome Measures in Rheumatology.

Clinical outcomes with higher starting doses of methotrexate were examined in disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis.

Study examines whether cardiovascular disease risk algorithms may be more useful if paired with imaging technology in patients with RA.

A damage index to measure morbidity caused by the 4 most common monogenic autoinflammatory diseases has been developed by a consortium working under the auspices of the European Union’s ERA-NET PRIOMEDCHILD.

Trajectory modeling of axial SpA is feasible and suggests up to a third of patents may be under-treated.

Existing data suggest that glucocorticoid use puts patients with RA at risk for developing cataracts, but data on the parameters of risk remain too sparse to form a definitive stance.

The oral Janus kinase inhibitor baricitinib may offer an alternative treatment for those who cannot tolerate or whose rheumatoid arthritis does not respond adequately to conventional disease-modifying antirheumatic drugs and/or biologic disease-modifying antirheumatic drugs.

Tapering of anti-TNF therapy can facilitate sustained remission or lower disease activity in most patients with axial spondyloarthritis while ameliorating both risk for adverse events and treatment costs.

Results of an open-label extension of the EMBLEM randomized controlled trial confirm that the novel B-cell modulator epratuzumab is associated with improvements in disease activity and quality of life in patients with moderate to severe systemic lupus erythematosus.

Methotrexate (MTX) dosage does not impact the efficacy of certolizumab pegol (CZP) in patients with rheumatoid arthritis receiving combination therapy, suggesting that MTX dose modification is feasible without compromising efficacy.

A multidisciplinary EULAR task force reviewed the literature on dose-dependent risks related to glucocorticoid therapy in the management of chronic inflammatory rheumatic disease.